VEGFA and non-small cell lung carcinoma: Although the usage of anti-VEGF led to an increased breast CSCs, through induction of hypoxia [262], in the CSCs population of NSCLC, combination therapy of anti-hepatoma-derived growth factor (HDGF) antibody and VEGF tyrosine kinase inhibitor was successful in diminishing this population [323].